AUSTIN, Texas and HAMILTON, ON and SAN DIEGO , March 12, 2025 /PRNewswire/ -- Triumvira Immunologics , a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced it will present at the 2025 SITC Spring Scientific, Cellular Therapy and Solid Tumors Conference in San Diego, California , from March 12-14, 2025 . The poster presentation, titled "A Phase 1/2 Study on the Safety and Efficacy of Autologous TAC T Cells in Subjects with Claudin 18.2+ Advanced Solid Tumors," will provide a detailed overview of interim findings from the Phase 1/2 study (TACTIC-3 / NCT05862324 ).
The TAC technology platform, demonstrated by TAC01-CLDN18.2, reprograms T cells to harness the natural T cell receptor (TCR) signaling complex, enabling precise tumor targeting while minimizing systemic toxicity compared to conventional engineered T cell therapies. "We are excited to share the latest clinical data from our ongoing TACTIC-3 study at the 2025 SITC Spring Scientific Conference.
These interim findings further reinforce the potential of our TAC technology to deliver safe and effective cell therapies for patients with Claudin 18.2+ advanced solid tumors," said Robert Williamson, President of Triumvira Immunologics. "At Triumvira, we remain committed to pioneering innovative T cell therapies that harness the natural biology of T cells, offering new hope to patients with.
